Trusted Insighthttp://thetrustedinsight.com/2024-03-19T11:01:06.238686-04:00Trusted Insight, the world's largest platform for institutional investors with 40,000 LP investor professionals in 98 countries and territories around the globe. 30,000 institutional investors engage with Trusted Insight each week. They are actively investing in alternative assets, primarily private equity, hedge funds, real estate and private companies. Our users consist of pension funds, endowments, foundations, sovereign wealth funds, family offices, banks and insurance companies. 83% of Trusted Insight users continue to use the platform 6 months after initially signing up. Investors on the platform, on average manage in excess of $5 billion. We are a platform for qualified purchasers, not high net worth investors.
3 Potential Biotech Buyout Targets In 2024
2024-03-19T11:01:06.238686-04:00https://www.thetrustedinsight.com/investment-news/3-potential-biotech-buyout-targets-in-2024-20240319385/
The biotech sector saw a surge of M&A activity at the end of 2023. Major deals to acquire ImmunoGen, Inc. (IMGN), Cerevel Therapeutics Holdings, Inc. (CERE) and Karuna Therapeutics, Inc. (KRTX) all took place in the final five weeks of last year. Each purchase contained a substantial buyout premium as well for shareholders. The uptick in deal volume was one of key drivers of the 50% rally that took place from the SPDR® S&P Biotech ETF (XBI) off its late October lows. That rally has ebbed in recent weeks as has new deal flow.
Alumis Raises $259M In 2024's Largest Biotech Round So Far
2024-03-06T11:41:07.106470-05:00https://www.thetrustedinsight.com/investment-news/alumis-raises-259m-in-2024s-largest-biotech-round-so-far-20240306940/
Alumis closes $259M series C in year's largest private biotech fundraise yet
gmasson
Tue, 03/05/2024 - 17:22.:
Alumis has reeled in an eye-watering $259 million series C financing that will support a pipeline of oral therapies designed to tackle immune dysfunction and help launch a phase 3 psoriasis trial for lead asset ESK-001. It marks the biggest haul for a private biotech so far in 2024, according to Fierce Biotech’s Fundraising Tracker.
Vc Closes $260M Fund For Early-stage Biotechs
2024-02-22T12:41:05.906940-05:00https://www.thetrustedinsight.com/investment-news/vc-closes-260m-fund-for-early-stage-biotechs-20240222497/
'Golden era of innovation': ORI Capital raises $260M fund for early-stage biotechs
gmasson
Thu, 02/22/2024 - 10:20.:
ORI Capital has raised $260 million, the venture capital firm’s second life sciences fund that will go toward early-stage biotechs worldwide. The Hong Kong- and U.S.-based investment firm will support companies focused on diagnostics, therapeutics and drug delivery for conditions with large unmet need and high mortality rates, according to a Feb. 22 release. Those indications include cancer, metabolic disorders and neurodegenerative diseases, ORI said.
Tyneside Biotech Startup Glycanage Completes $4.2M Fundraise
2024-02-20T12:41:06.614164-05:00https://www.thetrustedinsight.com/investment-news/tyneside-biotech-startup-glycanage-completes-42m-fundraise-20240220428/
The innovator will use the new capital to move into the broader diagnostics market. :
Tyneside biotech startup GlycanAge has completed a $4.2m fundraise to ramp up a roll-out of its biological age test into new markets. The Newcastle business has completed the funding round which was led by venture capital firm LAUNCHub Ventures and deep-tech investors Kadmos Capital. Based in The Catalyst at the city’s science hub Newcastle Helix, GlycanAge offers a biological age test that uses glycan biomarkers to enable early prevention strategies for both consumers and healthcare professionals.
Fierce Biotech Fundraising Tracker 2024
2024-01-04T12:36:09.985886-05:00https://www.thetrustedinsight.com/investment-news/fierce-biotech-fundraising-tracker-2024-20240104882/
Fierce Biotech Fundraising Tracker '24: HI-Bio secures $95M; Radionetics raises $52.5M
gmasson
Tue, 01/02/2024 - 12:12.:
A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's tracker, including any fundraising rounds north of $50 million this time around. We'll still profile exciting new companies and larger rounds in-depth, while we focus more coverage on clinical trial results, special reports and enterprise stories.
Goldman Sachs Closes $650M Fund Aimed At Biotechs
2024-01-03T11:01:07.149330-05:00https://www.thetrustedinsight.com/investment-news/goldman-sachs-closes-650m-fund-aimed-at-biotechs-20240103833/
‘An attractive opportunity for investing’: Goldman Sachs closes $650M fund aimed at biotechs
jwaldron
Wed, 01/03/2024 - 09:14.:
Goldman Sachs is planning to make a splash in the life sciences sector, taking in $650 million for its first fund aimed at the drug development space. The size of the West Street Life Sciences I fund, which overshot its original target, makes it one of the largest first-time private life sciences growth funds, Goldman Sachs Asset Management claimed in a Jan. 3 release.
Biotech Companies Tap Saudi Arabia For Venture Funding
2023-11-10T08:31:18.909949-05:00https://www.thetrustedinsight.com/investment-news/biotech-companies-tap-saudi-arabia-for-venture-funding-20231110879/
Slowing U.S. venture investment is spurring startups to consider investors from the oil-rich country. :
Some biotechnology startups are raising capital from Saudi Arabia as U.S. venture funding retreats and Middle East countries seek to boost their life-sciences industries. Chicago-based Flashpoint Therapeutics recently raised seed financing led by Beta Lab, a new venture firm based in Riyadh, and biomedical startups including Insilico Medicine have secured funding from Prosperity7 Ventures, the venture fund of Aramco Ventures, a subsidiary of Saudi Arabia’s national oil company.
Bioluminescence Enters Biotech Venture Spotlight With $477M
2023-11-01T10:31:06.196946-04:00https://www.thetrustedinsight.com/investment-news/bioluminescence-enters-biotech-venture-spotlight-with-477m-20231101454/
Bioluminescence enters biotech venture spotlight with almost $500M under management
mbayer
Tue, 10/31/2023 - 16:17.:
Bioluminescence is rocketing out of stealth, looking to warm a frigid funding environment with the embrace of fresh funding. The new venture capital outfit is entering the fold with $477 million in assets under management across two funds, including investments in startups like genetic-medicines-focused ReCode Therapeutics and neuroscience biotech Nido Biosciences, according to Wednesday’s unveiling. The two funds are Bioluminescence Ventures Fund I and II, respectively. “Innovation never stops, even when financing does,” Founding and Managing Partner Kouki Harasaki, Ph.D., said in a release.
These Biotech Companies Are Poised For Big Things In 2023 And Beyond
2023-09-30T13:31:06.295761-04:00https://www.thetrustedinsight.com/investment-news/these-biotech-companies-are-poised-for-big-things-in-2023-and-beyond-20230930117/
read more. :
Biotech companies continue to live up to their hype, with many of them reaching new heights in 2023. But that doesn't mean they've peaked. There's plenty more room for growth throughout the rest of the year and beyond. TrialSpark is a tech-driven pharmaceutical company set apart by its exceptionally efficient approach to drug development. The company has established a technology platform that enhances every facet of drug development, leading to optimized trial design, faster trial completion and superior trial data quality.
South West Biotechnology Company Completes Funding Round With £500,000 Support
2023-09-27T07:11:36.907274-04:00https://www.thetrustedinsight.com/investment-news/south-west-biotechnology-company-completes-funding-round-with-500000-support-20230927940/
Molendotech is the latest business to be supported by the Cornwall and Isles of Scilly Investment Fund. :
Molendotech is the latest business to be supported by the Cornwall and Isles of Scilly Investment Fund A South West research and development company has secured £500,000 from the Cornwall and Isles of Scilly Investment Fund (CIOSIF). Molendotech has secured the investment as part of an oversubscribed £1m funding round, which includes investment from appointed CIOSIF fund manager, The FSE Group, Exeter based VC firm QantX, a number of existing private investors and the management team.
Andreessen Co-leads $200M Investment In Biotech Startup Genesis Therapeutics
2023-08-21T09:32:06.534058-04:00https://www.thetrustedinsight.com/investment-news/andreessen-co-leads-200m-investment-in-biotech-startup-genesis-therapeutics-20230821456/
Genesis plans to use the funding to help drugs discovered with artificial intelligence enter clinical trials. :
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit https://www.djreprints.com. https://www.wsj.com/articles/andreessen-co-leads-200-million-investment-in-biotech-startup-genesis-therapeutics-6c303ba8 Venture firm Andreessen Horowitz has co-led a $200 million investment in Genesis Therapeutics, a biotechnology startup that uses artificial intelligence to discover medicines against molecular targets that have thwarted drugmakers. Genesis is one of several companies applying AI in an effort to uncover novel medicines and make drug discovery more successful.
Gracell Biotechnologies Inc. (grcl) Q2 2023 Earnings Call Transcript
2023-08-14T12:01:06.552909-04:00https://www.thetrustedinsight.com/investment-news/gracell-biotechnologies-inc-grcl-q2-2023-earnings-call-transcript-20230814166/
Gracell Biotechnologies Inc. (NASDAQ:GRCL) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Ladies and gentlemen, thank you for standing by. My name is Bhavesh, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Gracell Biotechnologies Second Quarter 2023 Earnings Conference Call. At this time, all lines have been placed on mute to prevent any background noise. [Operator Instructions] Good morning and welcome to Gracell’s second quarter 2023 corporate update conference call on the webcast.
Molten Ventures Joins $54M Funding Round Of Biotech Firm Evonetix
2023-02-07T13:01:11.498380-05:00https://www.thetrustedinsight.com/investment-news/molten-ventures-joins-54m-funding-round-of-biotech-firm-evonetix-20230207004/
Molten Ventures, one of Europe’s most well-known venture capital firms focusing on high-growth tech start-ups, has joined a Series B funding round of UK biology company Evonetix. The $24m funding round extension was led by Foresite Capital and included other early-stage investors such as Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence. The extension brings Evonetix’s total Series B funding to $54m. This investment will be used to help bring its semiconductor chips to commercial scale. Based in Cambridge, Evonetix is developing its own silicon chip to control the synthesis of DNA.
Miles Gl Capital Partners With 57 Capital Advisors To Expand To Biotech Investment
2023-01-23T09:31:33.850627-05:00https://www.thetrustedinsight.com/investment-news/miles-gl-capital-partners-with-57-capital-advisors-to-expand-to-biotech-investment-20230123378/
NEW YORK, Jan. 23, 2023 /PRNewswire/ -- Miles GL Capital today introduces the partnership with 57 Capital Advisors, a biotech venture capital firm in New York. Miles GL will add biotech coverage and become a multi-sector hedge fund focusing on both technology and biotech. Dr. Lei Zhong, from 57 Capital Advisors, will join the company as the Senior Partner and Portfolio Manager to lead biotech investment. A team of medical scientists, in association with 57 Capital, will support Dr. Zhong at Miles GL. "This is a meaningful expansion of Miles GL Capital."
Biotech Industry Leaders Share Cautious Optimism For 2023 Amid Downturn And Layoffs – Geekwire
2022-12-27T12:31:31.342258-05:00https://www.thetrustedinsight.com/investment-news/biotech-industry-leaders-share-cautious-optimism-for-2023-amid-downturn-and-layoffs-geekwire-20221227363/
Sujal Patel has been here before. He weathered the 2009 recession as CEO of Isilon Systems, coming out the other end to sell his company the next year for $2.25 billion. He’s now CEO of Nautilus Biotechnology, and he’s not taking any big chances in the current economic downturn. “As a development stage company, we’re doing everything we can to strike the right balance between accelerating the development of our platform while seeking to extend our cash runway,” said Patel.
10 Biotech Stocks With The Biggest Upside
2022-12-13T17:01:07.363573-05:00https://www.thetrustedinsight.com/investment-news/10-biotech-stocks-with-the-biggest-upside-20221213889/
In this article, we discuss the 10 biotech stocks with the biggest upside. If you want to read about some more biotech stocks with the biggest upside, go directly to 5 Biotech Stocks With The Biggest Upside. The biotechnology sector has been one of the most profitable growth spaces in the stock market over the past few years. Investors are thus always looking for potential bargains in the industry that might pay off handsomely in the coming years.
Time Bioventures Raises $100M For Debut Biotech Fund
2022-10-28T07:06:35.516967-04:00https://www.thetrustedinsight.com/investment-news/time-bioventures-raises-100m-for-debut-biotech-fund-20221028747/
The early-stage life sciences venture firm's limited partners include Chris Sacca, Ron Burkle and Wildcat Partner Holdings.
Twinstrand Ceo And Co-founder Steps Down From Seattle Biotech Startup Amid Reported Layoffs – Geekwire
2022-10-07T16:31:15.042070-04:00https://www.thetrustedinsight.com/investment-news/twinstrand-ceo-and-co-founder-steps-down-from-seattle-biotech-startup-amid-reported-layoffs-geekwire-20221007779/
TwinStrand Biosciences’ co-founder Jesse Salk has stepped down from the CEO role, according to a statement issued by the Seattle biotech company Friday. Salk will remain as chief scientific officer and a member of the board. Healthcare industry veteran Chad Brown, a former exec at Nanostring and Qiagen, has stepped in as interim CEO. Brown is also a board member at TwinStrand. The leadership change comes amid reports of layoffs at the 7-year-old gene sequencing startup. Several employees posted on LinkedIn this week about being laid off, with some noting that “nearly 50%” of the company’s workforce was cut.
Biotech Startup Eyestem Raises $6.4 Mn To Build Cell Therapy Products
2022-08-08T07:11:05.600288-04:00https://www.thetrustedinsight.com/investment-news/biotech-startup-eyestem-raises-64-mn-to-build-cell-therapy-products-20220808866/
Bengaluru-based biotech startup Eyestem has secured $6.4 Mn (INR 51 Cr) in its Series A funding round at a post-money valuation of $46.4…
Seattle Biotech Startup Ozette Lands $26M From Microsoft, Madrona, Others To Analyze Immune Cells – Geekwire
2022-07-28T09:31:06.210481-04:00https://www.thetrustedinsight.com/investment-news/seattle-biotech-startup-ozette-lands-26m-from-microsoft-madrona-others-to-analyze-immune-cells-geekwire-20220728462/
The news: Single cell analysis startup Ozette Technologies, with deep roots in the Seattle academic and startup community, has raised $26 million. The company’s tools enable its academic and biopharma partners to pinpoint and quantify immune cell types from massive datasets. The tools support clinical trials and other research. The background: Ozette spun out of Fred Hutchinson Cancer Center in 2020; was incubated at the Allen Institute for Artificial Intelligence (AI2); and fueled by a $6 million seed funding round led last year by Seattle’s Madrona Venture Group.
Frazier Healthcare Partners To Bring Dutch Biotech Company Public In Spac Deal – Geekwire
2022-07-25T15:31:06.526977-04:00https://www.thetrustedinsight.com/investment-news/frazier-healthcare-partners-to-bring-dutch-biotech-company-public-in-spac-deal-geekwire-20220725334/
Frazier Healthcare Partners’ SPAC has found a partner. The longstanding Seattle-based venture firm inked a deal to bring Dutch biotech company NewAmsterdam Pharma public through a merger with its blank check company founded in 2020, Frazier Lifesciences Acquisition Corp (FLAC). New Amsterdam is expected to raise $373 million from the deal, which was sweetened with a $235 million PIPE (private investment in public equity) co-led by Frazier and Bain Capital Life Sciences. Frazier raised $138 million for its SPAC in late 2020. The deal comes as investor sentiment towards SPACs has deteriorated.
Biotech Startup String Raises $20 Mn To Offer Sustainable Solutions
2022-07-11T07:06:08.656128-04:00https://www.thetrustedinsight.com/investment-news/biotech-startup-string-raises-20-mn-to-offer-sustainable-solutions-20220711700/
Biotech startup String has raised $20 Mn in its Series B funding round led by Woodside Energy, a subsidiary of…
Biotech Food Colorant Startup Phytolon Closes $14.5M Series A Funding Round, Led By Dsm Venturing
2022-07-07T07:11:05.663222-04:00https://www.thetrustedinsight.com/investment-news/biotech-food-colorant-startup-phytolon-closes-145m-series-a-funding-round-led-by-dsm-venturing-20220707579/
YOKNEAM ILLIT, Israel , July 7, 2022 /PRNewswire/ -- Phytolon, a developer of fermentation-based natural food colors, announced today it has secured $14.5 million in funding, led by DSM Venturing, to further progress its technology towards commercialization, with participation from Cibus...
Arch Venture Partners Raises Close To $3B For Early-stage Biotech Fund – Geekwire
2022-06-29T21:41:06.706675-04:00https://www.thetrustedinsight.com/investment-news/arch-venture-partners-raises-close-to-3b-for-early-stage-biotech-fund-geekwire-20220629248/
ARCH Venture Partners has closed a $2.975 billion fund targeted for early-stage biotech companies. The firm’s 12th venture fund comes on the heels of a nearly $2 billion fund announced in January 2021 and launches amidst a biotech bear market. “Science doesn’t care what markets are doing, and science moves forward,” said ARCH cofounder and managing director Robert Nelsen in a statement announcing the fund Wednesday. ARCH has offices in Seattle and is a backer of Seattle-area giants Sana Biotechnology and Lyell Immunopharma.
Biotechs Face ‘funding Sahara’ As Easy Money Runs Dry | Financial Times
2022-06-22T07:01:48.062658-04:00https://www.thetrustedinsight.com/investment-news/biotechs-face-funding-sahara-as-easy-money-runs-dry-financial-times-20220622870/
Early-stage drugmakers face difficult decisions as public markets turn hostile. :
As Genocea ran low on cash in 2018, investors offered the US biotech a lifeline that allowed it to shift focus from developing a vaccine for genital herpes to targeting cancer treatments. There was no such safety net in May, when another cash crunch forced the 16-year-old group to fold. “A year ago Genocea probably could have raised enough cash to stay afloat until it could finish trials on its personalised cancer medicines,” said Daina Graybosch, analyst at SVB Leerink. Now, however, “the world has changed for biotech companies”.
Ai-powered Hong Kong Biotech Startup Raises $60M From Top Vcs Including B Capital, Qiming
2022-06-07T07:06:34.216730-04:00https://www.thetrustedinsight.com/investment-news/ai-powered-hong-kong-biotech-startup-raises-60m-from-top-vcs-including-b-capital-qiming-20220607107/
To date, Insilico Medicine has raised more than $360 million, including a Series C funding round of $255 million in June last year.
Biotech Company Pepgen Sets Ipo Price Range
2022-05-02T08:01:05.622762-04:00https://www.thetrustedinsight.com/investment-news/biotech-company-pepgen-sets-ipo-price-range-20220502427/
PepGen Inc. said Monday it expects its initial public offering of 7.8 million shares to price between $13 and $15 a share in a bid to raise about $109 million, based on the midpoint of its price range. The Cambridge, Mass., developer of medicine to treat Duchenne muscular dystrophy plans to trade on the Nasdaq under the symbol "PEPG" with underwriters BofA Securities, SVB Securities, Stifel and Wedbush PacGrow. Principal shareholders of PepGen include Viking Global Partners LLC, entities affiliated with RA Capital and Oxford Science Enterprises plc.
Hillevax Sets Ipo Terms, Valuing The Biotech At Up To $543M
2022-04-25T08:01:16.197347-04:00https://www.thetrustedinsight.com/investment-news/hillevax-sets-ipo-terms-valuing-the-biotech-at-up-to-543m-20220425044/
HilleVax Inc. has set terms for its initial public offering, in which the Massachusetts-based biopharmaceutical company that focuses on developing novel vaccines looks to raise up to $185.3 million. The company said it is offering 10.29 million shares in the IPO, which is expected to price between $16 and $18 a share. With 30.19 million shares expected to be outstanding after the IPO, the expected pricing range could value the company at up to $543.45 million. HilleVax's stock is expected to list on the Nasdaq under the ticker symbol "HLVX."
Vision: Deerfield Management And Kkr Invest In Cell Therapy Company Aurion Biotech
2022-04-16T14:31:11.987254-04:00https://www.thetrustedinsight.com/investment-news/vision-deerfield-management-and-kkr-invest-in-cell-therapy-company-aurion-biotech-20220416628/
Seattle-based Aurion Biotech is a developer of regenerative therapies for vision loss. Aurion Biotech secured a US$ 120 million financing that was led by Deerfield Management, and included existing investors Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, an ophthalmology-focused investment platform supported by KKR, and Visionary Ventures, a ophthalmology-focused venture fund. Alcon also…
Biotech Money Shock: Investors Unwind Speculative Bets As Pandemic Fears Fade
2022-02-14T07:01:06.548220-05:00https://www.thetrustedinsight.com/investment-news/biotech-money-shock-investors-unwind-speculative-bets-as-pandemic-fears-fade-20220214398/
(Bloomberg) -- The first year of the Covid-19 pandemic fueled a frenzy for biotechnology stocks. Now, with vaccines in millions of arms and the omicron variant on the wane, there are signs investors are ready to move on. After cresting at nearly $5 billion a month in early 2020, inflows into health-care funds have slowed to a more modest $800 million a month, according to data compiled by Bloomberg Intelligence.
Eikon Therapeutics Snares $500M Series B, Pinning Constellation Of Biotech Stars To Its Upper Ranks
2022-01-06T08:31:05.910529-05:00https://www.thetrustedinsight.com/investment-news/eikon-therapeutics-snares-500m-series-b-pinning-constellation-of-biotech-stars-to-its-upper-ranks-20220106109/
Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranks
fkansteiner
Wed, 01/05/2022 - 15:18.:
Eikon Therapeutics, the drug discovery startup with a former Merck & Co. research chief at the helm, has appointed a pantheon of biotech veterans on its quest to take its live-cell imaging platform to the next level. The biotech unveiled the hiring of six new executives as it pulled back the curtain on a more than half-a-billion-dollar fundraising round Thursday.
Apollo's Mission To Extend Human Health Span Gets $180M Boost, Giving Vc Fund A Launchpad For Age-related Disease Biotechs | Fiercebiotech
2021-12-01T09:11:06.744188-05:00https://www.thetrustedinsight.com/investment-news/apollos-mission-to-extend-human-health-span-gets-180m-boost-giving-vc-fund-a-launchpad-for-age-related-disease-biotechs-fiercebiotech-20211201251/
Apollo's mission to extend human health span gets $180M boost, giving VC fund a launchpad for age-related disease biotechs
ntaylor
Wed, 12/01/2021 - 04:50.
Female-owned Biotech Startup Tiamat Sciences Raises $3M To Manufacture Plant-based Biomolecules
2021-11-24T20:41:07.156207-05:00https://www.thetrustedinsight.com/investment-news/female-owned-biotech-startup-tiamat-sciences-raises-3m-to-manufacture-plant-based-biomolecules-M25h6JVmHmWkiHTWUcJrQT-20211124966/
List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro
Database is the most reliable, up-to-date and affordable venture
capital directory
2021 EDITION SPECIAL OFFER! Buy Now for only $119.95 plus a FREE update in January
2022
Learn More
or
Buy Now
VCPro Database 2021
24th Edition --
a downloadable and searchable venture capital database with
6,500+ venture capital and private equity firms
worldwide.
Female-owned Biotech Startup Tiamat Sciences Raises $3M To Manufacture Plant-based Biomolecules
2021-11-24T11:31:37.307430-05:00https://www.thetrustedinsight.com/investment-news/female-owned-biotech-startup-tiamat-sciences-raises-3m-to-manufacture-plant-based-biomolecules-20211124950/
DURHAM, N.C., Nov. 24, 2021 /PRNewswire/ -- Biotechnology startup Tiamat Sciences today announced its $3 million seed financing round led by Silicon Valley venture capital firm True Ventures with participation from Social Impact Capital and Cantos. Tiamat Sciences manufactures animal-free...
Arbor Biotechnologies Closes $215M Oversubscribed Series B Financing To Advance Next-generation Precision Editing Therapeutics
2021-11-09T20:31:10.357217-05:00https://www.thetrustedinsight.com/investment-news/arbor-biotechnologies-closes-215m-oversubscribed-series-b-financing-to-advance-next-generation-precision-editing-therapeutics-20211109944/
List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro
Database is the most reliable, up-to-date and affordable venture
capital directory
2021 EDITION SPECIAL OFFER! Buy Now for only $119.95 plus a FREE update in January
2022
Learn More
or
Buy Now
VCPro Database 2021
24th Edition --
a downloadable and searchable venture capital database with
6,500+ venture capital and private equity firms
worldwide.
Biotech Startup Mekonos Raises Oversubscribed $25M Round To Overcome Pharma Industry's Cell & Gene Therapy Delivery Hurdles
2021-11-09T11:31:16.528703-05:00https://www.thetrustedinsight.com/investment-news/biotech-startup-mekonos-raises-oversubscribed-25m-round-to-overcome-pharma-industrys-cell-gene-therapy-delivery-hurdles-20211109914/
SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New...
How Pandemic-driven Talent Migration Will Change Where Biotech Companies Are Located
2021-10-25T15:31:16.847227-04:00https://www.thetrustedinsight.com/investment-news/how-pandemic-driven-talent-migration-will-change-where-biotech-companies-are-located-20211025933/
Joel Marcus’ fortunes have risen with those of the life sciences industry. The executive chairman of life sciences builder Alexandria Real Estate Equities first bought laboratory space in Seattle in 1996, two years after founding the company when biotech was still emerging as an industry. Alexandria is now a publicly traded giant with a market cap of more than $30 billion, millions of square feet of lab space throughout the U.S. and a venture capital arm, Alexandria Venture Investments. And his Pasadena, Calif.-based company has helped make the Seattle area one of the country’s top ten biotech clusters.
Amplo Biotechnology Closes Series Seed Financing To Advance Gene Therapies For The Treatment Of Neuromuscular Junction Disorders
2021-10-06T23:36:16.361094-04:00https://www.thetrustedinsight.com/investment-news/amplo-biotechnology-closes-series-seed-financing-to-advance-gene-therapies-for-the-treatment-of-neuromuscular-junction-disorders-20211006824/
List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro
Database is the most reliable, up-to-date and affordable venture
capital directory
2021 NEW EDITION NOW AVAILABLE! Buy Now for $119.95 with a free annual update in January
2022
Learn More
or
Buy Now
VCPro Database 2021
24th Edition --
a downloadable and searchable venture capital database with
6,500+ venture capital and private equity firms
worldwide.
Mpm Capital Raises Biotech’s Largest Impact Investment Fund To Help Finance The Fight Against Cancer And Other Diseases
2021-10-06T23:36:12.723513-04:00https://www.thetrustedinsight.com/investment-news/mpm-capital-raises-biotechs-largest-impact-investment-fund-to-help-finance-the-fight-against-cancer-and-other-diseases-20211006823/
List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro
Database is the most reliable, up-to-date and affordable venture
capital directory
2021 NEW EDITION NOW AVAILABLE! Buy Now for $119.95 with a free annual update in January
2022
Learn More
or
Buy Now
VCPro Database 2021
24th Edition --
a downloadable and searchable venture capital database with
6,500+ venture capital and private equity firms
worldwide.
Early Stage Venture Capital Firm Nfx Launches $450M Fund To Support Startups In Sectors Including Crypto, Fintech And Biotech
2021-10-05T10:01:42.412244-04:00https://www.thetrustedinsight.com/investment-news/early-stage-venture-capital-firm-nfx-launches-450m-fund-to-support-startups-in-sectors-including-crypto-fintech-and-biotech-20211005689/
Morgan Beller, NFX general partner and co-creator of Facebook’s cryptocurrency Libra (Diem), will help lead the fund’s crypto investments. :
Morgan Beller, NFX general partner and co-creator of Facebook’s cryptocurrency Libra (Diem), will ... [+] help lead the fund’s crypto investments. Early-stage venture firm NFX, whose portfolio includes billion-dollar companies such as Lyft
LYFT
, Doordash, Patreon and Poshmark, announced a new venture fund today. The $450 Million Fund III will target crypto alongside emerging verticals such as fintech, proptech, marketplaces, gaming, and tech-bio and is the firm’s largest to date.
Top Biotech Stocks To Watch After Bristol Myers’ Opdivo Sees Q2 Growth
2021-07-28T14:01:06.185439-04:00https://www.thetrustedinsight.com/investment-news/top-biotech-stocks-to-watch-after-bristol-myers-opdivo-sees-q2-growth-20210728379/
Hot biotech stocks to watch right now as cancer treatments make headlines in 2021.:
Just one day after Merck’s (NYSE:MRK) blockbuster FDA approval news, Bristol-Myers Squibb (NYSE:BMY) added more fuel to the fire. Cancer treatments have remained a hotbed for biotech companies. Now the R&D from years past seems to have begun paying off. Wednesday morning Bristol-Myers reported its second-quarter earnings. After dissecting the data, there are several significant things to take away from these results. First, the biotech company is back to growth. The company reported an increase of 16% year-over-year in quarterly revenue with $11.7 billion.
Pillar Vc Closes $192M For Two Funds Targeting Saas, Crypto, Biotech, Manufacturing – Techcrunch
2021-07-20T10:11:06.667983-04:00https://www.thetrustedinsight.com/investment-news/pillar-vc-closes-192m-for-two-funds-targeting-saas-crypto-biotech-manufacturing-techcrunch-20210720763/
As its name suggests, venture firm Pillar VC is focused on building "pillar" companies in Boston and across the Northeast.
Eliem Therapeutics Files For Ipo As Another Seattle-area Biotech Firm Set To Go Public
2021-07-19T17:01:06.014159-04:00https://www.thetrustedinsight.com/investment-news/eliem-therapeutics-files-for-ipo-as-another-seattle-area-biotech-firm-set-to-go-public-20210719700/
Eliem Therapeutics, a clinical stage biotech company generating therapies for pain, depression and other nervous-system related conditions, has filed to go public via an IPO. The company’s filing with the U.S. Securities and Exchange Commission comes on the heels of two rounds of private funding already this year tallying $140 million, including a $60 million Series B round in May. The Redmond, Wash.-based company was founded in 2019 and plans to list on the Nasdaq under the symbol ELYM. It aims to raise up to $80 million with the IPO.
Perceptive Advisors Joins Biotech Investment Boom With $515M Fund
2021-05-12T07:41:06.488503-04:00https://www.thetrustedinsight.com/investment-news/perceptive-advisors-joins-biotech-investment-boom-with-515m-fund-20210512276/
Summary List PlacementInvestors keep pouring cash into biotech, and the surge just helped investment firm Perceptive Advisors raise a new venture fund that's more than double the size of its previous one. Perceptive, which is based in New York, raised $515 million for its second Perceptive Xontogeny Fund, the firm told Insider. Perceptive raised $210 million for its first Xontogeny Fund in 2019. The fund's name references the accelerator Perceptive has a stake in, Xontogeny, led by biotech veteran Chris Garabedian.
China Money Podcast: Robotics, Biotech And Electric Vehicle Startups Clear Funding Hurdles – China Money Network
2021-04-16T22:01:07.407822-04:00https://www.thetrustedinsight.com/investment-news/china-money-podcast-robotics-biotech-and-electric-vehicle-startups-clear-funding-hurdles-china-money-network-20210416655/
In this episode of China Money Podcast, listen to all the news headlines in the China venture investment and tech sector for the week ending April 16. We are at the midpoint of the month of April, and we recorded 58 different startup, growth stage, and pre-IPO investment deals closing in the past 5 days […]
China Money Podcast: Robotics, Biotech And Electric Vehicle Startups Clear Funding Hurdles comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
Ag Biotech Pioneer Fraley Joins Trace Genomics Board
2021-04-15T15:01:06.479479-04:00https://www.thetrustedinsight.com/investment-news/ag-biotech-pioneer-fraley-joins-trace-genomics-board-20210415542/
REDWOOD CITY, Calif., April 15, 2021 /PRNewswire/ -- Trace Genomics announces the appointment of Dr. Robert (Robb) Fraley to its board of directors. Dr. Fraley, who served for nearly 40 years as chief technology officer at Monsanto and helped develop the first genetically modified seed,...
Benchling Raises $200M Series E To Accelerate Biotech R&d
2021-04-14T09:01:11.025828-04:00https://www.thetrustedinsight.com/investment-news/benchling-raises-200m-series-e-to-accelerate-biotech-rd-20210414426/
SAN FRANCISCO, April 14, 2021 /PRNewswire/ -- Benchling, the leading life sciences R&D cloud, has raised $200 million in Series E funding led by Sequoia Capital Global Equities and joined by Altimeter Capital, Byers Capital and Elad Gil. Existing investors participated, including Thrive...
Seattle Biotech Startup Outpace Bio Raises $30M To Fight Cancer With Custom-designed Proteins
2021-03-31T11:11:06.204859-04:00https://www.thetrustedinsight.com/investment-news/seattle-biotech-startup-outpace-bio-raises-30m-to-fight-cancer-with-custom-designed-proteins-20210331463/
New funding: Outpace Bio raised a $30 million Series A investment round to design custom cell and gene-based therapies. The science: Founded in November, the Seattle startup is developing software and hardware to manipulate how cells interact with diseases. Its initial work is focused on T cell therapies that fight solid tumors. Partnership with Lyell: The 18-person company also announced a partnership with San Francisco startup Lyell Immunopharma to pursue commercialization of a potential immune cell therapy for cancer treatment. Investors: ARTIS Ventures and Lyell led the round.
Ra Capital, Juno Alum Launch Chronic Pain Biotech Eliem Therapeutics
2021-03-25T13:01:07.013122-04:00https://www.thetrustedinsight.com/investment-news/ra-capital-juno-alum-launch-chronic-pain-biotech-eliem-therapeutics-20210325025/
Summary List PlacementBiotech investors are flooding into the mental health and neuroscience fields, and RA Capital is the latest to get in on the trend. The venture capital firm launched Eliem Therapeutics on Thursday, after combining two biotechs it had been incubating for several years. Eliem raised a $39 million Series A extension round at a $145 million valuation, according to three sources, who asked not to be identified as they were not authorized to discuss financials publicly. Eliem now has $80 million in capital, which is expected to fund it through 2022, according to an investor at RA Capital.
Bioheng Biotech Raised $80M In Series B Financing To Advance Allogeneic Immuno-cell Therapies
2021-03-24T10:41:06.457020-04:00https://www.thetrustedinsight.com/investment-news/bioheng-biotech-raised-80m-in-series-b-financing-to-advance-allogeneic-immuno-cell-therapies-20210324919/
NANJING, China, March 24, 2021 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company dedicated on developing novel cellular immunotherapy for cancer, today announced that it had secured $80 million in Series B Financing. The Series B was co-led by GL Ventures,...
Biotech Startup Absci Raises $125m For ‘protein Printing’ Tech; Total Funding Up To $230M
2021-03-23T12:11:06.332407-04:00https://www.thetrustedinsight.com/investment-news/biotech-startup-absci-raises-125m-for-protein-printing-tech-total-funding-up-to-230m-20210323843/
New funding: Vancouver, Wash.-based biotech company AbSci raised $125 million in a round led by Casdin Capital and Redmile Group. The tech: Founded in 2011, AbSci’s “Protein Printing” technology is used to discover and manufacture complex biological molecules such as antibodies and insulin. The idea is to reduce failure rates and accelerate development of protein biomanufacturing. A big year: AbSci raised a $65 million Series E round in October. In January it acquired Denovium, a small startup that uses deep learning to analyze the function and behavior of proteins.
Biotech Startup Absci Lands Investment From Merck’s Vc Arm To Fuel ‘protein Printing’ Technology
2021-03-05T13:31:06.394875-05:00https://www.thetrustedinsight.com/investment-news/biotech-startup-absci-lands-investment-from-mercks-vc-arm-to-fuel-protein-printing-technology-20210305705/
Vancouver, Wash.-based biotech company AbSci raised an undisclosed amount of funding from pharmaceutical giant Merck. Founded in 2011, AbSci’s “Protein Printing” technology is used to discover and manufacture complex biological molecules such as antibodies and insulin. The investment comes from Merck’s Global Health Innovation Fund, which has $500 million under management. A SEC filing posted Feb. 26 notes a $70 million cash infusion for the company. AbSci declined to comment on the filing or provide financial details of the deal.
Abclonal Biotechnology Completes $93M Series C Financing
2021-02-22T22:06:09.659803-05:00https://www.thetrustedinsight.com/investment-news/abclonal-biotechnology-completes-93m-series-c-financing-20210222840/
Funding to Accelerate Life Science Research Reagents and In Vitro Diagnostics Raw Materials Production and Development WOBURN, Mass., February 22, 2021-- ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital. Other new and existing shareholders, such as Sigma Square Capital, Kinghall Ventures, and Lucion Capital, participated in the new round.
Lilly Asia Ventures Leads $90M Series B In Clinical-stage Biotech Firm Regor
2021-02-19T06:06:12.408656-05:00https://www.thetrustedinsight.com/investment-news/lilly-asia-ventures-leads-90m-series-b-in-clinical-stage-biotech-firm-regor-20210219667/
LAV is in the market raising $900m for LAV Fund VI, and $450m for LAV Fund VI Opportunities. The post Lilly Asia Ventures leads $90m Series B in clinical-stage biotech firm Regor appeared first on DealStreetAsia.
Neox Biotech Closes Us$30 Million Series A Round
2021-02-09T06:16:10.468183-05:00https://www.thetrustedinsight.com/investment-news/neox-biotech-closes-us30-million-series-a-round-20210209937/
BEIJING, Feb. 9, 2021 /PRNewswire/ -- neoX Biotech, a next-generation biotech company specializing in computational design for novel drug research and development, recently announced that it had raised US$30 million in Series A funding. The financing was co-led by Sky9 Capital and 5Y...
Jeff Bezos-backed Startup Nautilus Biotechnology Set To Go Public Via Spac At $900M Valuation
2021-02-08T12:31:06.658879-05:00https://www.thetrustedinsight.com/investment-news/jeff-bezos-backed-startup-nautilus-biotechnology-set-to-go-public-via-spac-at-900m-valuation-20210208888/
Nautilus Biotechnology, a Seattle-based biotech startup led by Isilon co-founder Sujal Patel, is the latest company to go public using a special purpose acquisition company, or SPAC. The deal, announced Monday morning, will inject approximately $350 million into Nautilus, which is developing a next-generation platform to analyze the human proteome, or the body’s full set of proteins. It values the company at $900 million. The company plans to raise $150 million as part of a merger with Arya Sciences Acquisition Corp III, a publicly-traded SPAC sponsored by existing Nautilus investor Perceptive Advisors.
6 Major Biotechs To Watch Tackling The Pandemic Pathogens Of Today And Tomorrow
2021-02-04T09:31:05.790785-05:00https://www.thetrustedinsight.com/investment-news/6-major-biotechs-to-watch-tackling-the-pandemic-pathogens-of-today-and-tomorrow-20210204649/
Summary List PlacementThe COVID-19 pandemic has upended everything we've ever known, and venture capitalist bets are no exception. With the possibility of evolving variants and the coronavirus becoming an endemic disease, major investors are rethinking the profitability of investing in infectious disease. Since most infectious diseases require only short-term treatment, pharma and biotech weren't motivated to develop new drugs in the space. Cami Samuels of Venrock considered infectious disease a bad investment as recently as March 2020, just as the global pandemic was hit. Almost a year later, Silicon Valley venture firm Andreessen Horowitz thinks otherwise.
Inside University of Rochester’s Tenured Team, Culture | Rob Rahbari, Senior Investment Officer & Assistant Treasurer | Q&A
2021-02-02T17:36:35.794307-05:00https://www.thetrustedinsight.com/investment-news/inside-university-rochesters-tenured-team-culture--20210202383/
Rob Rahbari is a senior investment officer and assistant treasurer at the University of Rochester, which he joined in 2013. In this interview, he discussed the tenure and culture of the investment team at the University of Rochester; the robust opportunity set that venture capital presents; and their gradual approach to new areas such as biotechnology.
Takeda Gi Veteran Parikh Takes Charge At 'molecular Machines' Biotech Moma Therapeutics
2021-02-01T11:01:06.553484-05:00https://www.thetrustedinsight.com/investment-news/takeda-gi-veteran-parikh-takes-charge-at-molecular-machines-biotech-moma-therapeutics-20210201362/
Takeda GI veteran Parikh takes charge at 'molecular machines' biotech MOMA Therapeutics
badams
Mon, 02/01/2021 - 09:22.:
After breaking cover last April to go after a whole new class of medicine, Third Rock Ventures' MOMA Therapeutics has grabbed a new chief to take the helm. Asit Parikh, M.D., Ph.D., joins the ambitious startup as its full-time president and CEO nine months after it got off an $86 million funding round led by VC Third Rock Ventures to systematically go after molecular machines, a family of more than 400 enzymes that others have only stumbled upon by chance.
Arch Raises $1.9B To Build Another Crop Of Breakthrough Biotechs
2021-01-29T10:01:08.041692-05:00https://www.thetrustedinsight.com/investment-news/arch-raises-19b-to-build-another-crop-of-breakthrough-biotechs-20210129194/
Arch raises $1.9B to build another crop of breakthrough biotechs
ntaylor
Fri, 01/29/2021 - 06:04.:
Arch Venture Partners has closed its largest fund to date. The new investment fund gives Arch $1.85 billion to support the creation and advancement of early-stage biotech companies. As with its earlier funds, Arch will use the money to place a wide range of bets, handing out $50,000 when appropriate but also dialing its investment up to $250 million to support grand plans such as its effort to transform biopharmaceutical manufacturing through Resilience.
A Look At The Booming Biotech Sector
2021-01-19T00:33:57.202543-05:00https://www.thetrustedinsight.com/investment-news/a-look-at-the-booming-biotech-sector-20210119412/
In Europe, the biotechnology and healthcare sector accounted for 20% of overall private equity investment in the first half of 2020, according to recent data.
Seattle Biotech Startup Altpep Raises $23.1M To Tackle Alzheimer’s And Related Diseases
2021-01-14T19:11:06.968650-05:00https://www.thetrustedinsight.com/investment-news/seattle-biotech-startup-altpep-raises-231m-to-tackle-alzheimers-and-related-diseases-20210114268/
AltPep, a Seattle-based biotech startup tackling amyloid protein disorders, has raised $23.1 million in a Series A funding round. The venture spun out the University of Washington in March 2019. Its founder and CEO is Valerie Daggett, a longtime professor in the Department of Bioengineering in the College of Engineering. AltPep is developing tools and treatments for diseases caused by amyloid proteins that are incorrectly folded and create harmful deposits. These deposits can lead to numerous amyloid diseases including Alzheimer’s, Parkinson’s, type-2 diabetes, some kinds of drug-resistant bacterial infections, and dozens more.
Well-funded Stealthy Biotech Startup Nautilus Hires Former Smartsheet, Isilon, Genapsys Execs
2021-01-05T10:01:06.687282-05:00https://www.thetrustedinsight.com/investment-news/well-funded-stealthy-biotech-startup-nautilus-hires-former-smartsheet-isilon-genapsys-execs-20210105582/
Sujal Patel is getting the band back together at his secretive new biotech startup Nautilus Biotechnology. The company is beefing up its executive team with three new additions: Chris Blessington, vice president of corporate marketing and communications Anna Mowry, vice president of finance and business operations Subra Sankar, senior vice president of product development Mowry and Blessington previously worked with Patel at Isilon Systems, a Seattle startup he co-founded and sold to EMC for $2.5 billion in 2010. Mowry was most recently at Igneous and spent time at Amazon Web Services.
Series A Financing Of 570 Million Yen Procured By Epsilon Molecular Engineering: A Next-generation Medium Sized Molecular Biotechnology-based Drug Discovery Firm | Business Wire
2020-12-23T06:01:07.576336-05:00https://www.thetrustedinsight.com/investment-news/series-a-financing-of-570-million-yen-procured-by-epsilon-molecular-engineering-a-next-generation-medium-sized-molecular-biotechnology-based-drug-discovery-firm-business-wire-20201223156/
SAITAMA, Japan--(BUSINESS WIRE)--After a capital increase in the initial closing of its series A round, with investments by Mitsubishi UFJ Capital and Real Tech Fund, Epsilon Molecular Engineering Inc. (EME), a Saitama University-based biotechnology startup, recently had its second closing. Following the initial closing for the series A round, with Mitsubishi UFJ Capital as the lead investor, EME received investments from Gunma Medical Engineering Vitalization Investments, which is run by the R.
Biotech Startup D3bio Completes $200M Series A Round – China Money Network
2020-11-18T18:01:06.489937-05:00https://www.thetrustedinsight.com/investment-news/biotech-startup-d3bio-completes-200m-series-a-round-china-money-network-20201118268/
Chinese biotech firm D3Bio has recently announced the completion of a US$200 million Series A financing. This round of financing is co-invested by Boyu Capital, Matrix Partners China, Sequoia China, Temasek and WuXi AppTec Venture Capital Fund. The funds raised will be used to support the company to develop its product pipeline portfolio for the […]
Biotech Startup D3Bio Completes $200 Million Series A Round comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
Chinese Biotech Startup D3 Bio Raises $200M In Series A Round
2020-11-18T06:01:09.405459-05:00https://www.thetrustedinsight.com/investment-news/chinese-biotech-startup-d3-bio-raises-200m-in-series-a-round-20201118184/
Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek and WuXi AppTec unit joined the round. The post Chinese biotech startup D3 Bio raises $200m in Series A round appeared first on DealStreetAsia.
Idg Leads $80M Series B Round In Chinese Biotech Firm Ptm Biolabs
2020-11-12T06:01:06.281904-05:00https://www.thetrustedinsight.com/investment-news/idg-leads-80m-series-b-round-in-chinese-biotech-firm-ptm-biolabs-20201112847/
Apart from its presence in China, PTM Biolabs also runs an affiliate in Chicago, the US. The post IDG leads $80m Series B round in Chinese biotech firm PTM Biolabs appeared first on DealStreetAsia.
Chinese Biotech Firm Recbio Raises Over $227.4M In Series B Round
2020-11-11T06:16:10.401076-05:00https://www.thetrustedinsight.com/investment-news/chinese-biotech-firm-recbio-raises-over-2274m-in-series-b-round-20201111792/
RecBio had raised 500 million yuan ($75.8 million) in a Series A round in January 2019. The post Chinese biotech firm RecBio raises over $227.4m in Series B round appeared first on DealStreetAsia.
Chinese Biotech Firm Genecast Secures $149M In Series E Round
2020-10-27T07:11:09.819262-04:00https://www.thetrustedinsight.com/investment-news/chinese-biotech-firm-genecast-secures-149m-in-series-e-round-20201027963/
The firm has completed at least six investment rounds. The post Chinese biotech firm Genecast secures $149m in Series E round appeared first on DealStreetAsia.
Biotech Sector Sees Huge PE, VC Investment Activity Jump As Covid Recovery Continues
2020-10-21T10:01:50.371252-04:00https://www.thetrustedinsight.com/investment-news/biotech-sector-sees-huge-pe-vc-investment-activity-jump-as-covid-recovery-continues-20201021656/
Private equity and venture capital investment in the biotech sector has scored its busiest month of the past 12 as markets continue their recovery from March’s coronavirus shock.
S Korean Exosome Biotech Firm Ilias Biologics Raises $20.6M In Series B Round
2020-09-30T07:01:09.643920-04:00https://www.thetrustedinsight.com/investment-news/s-korean-exosome-biotech-firm-ilias-biologics-raises-206m-in-series-b-round-20200930456/
The company's total funding stands to $40.2 million to date. The post S Korean exosome biotech firm ILIAS Biologics raises $20.6m in Series B round appeared first on DealStreetAsia.
Chinese Biotech Firm Biocytogen Raises Rmb970 Million – China Money Network
2020-09-15T21:31:08.502270-04:00https://www.thetrustedinsight.com/investment-news/chinese-biotech-firm-biocytogen-raises-rmb970-million-china-money-network-20200915720/
Chinese biotech company BioCytogen has recently completed a series D+ round of financing of RMB970 million yuan. This round of financing was led by CMB International, followed by SDIC Ventures, China Life Equity, Bencao Capital, Tongchuangweiye and Pax Capital. This financing will be mainly used to support the rapid implementation of the company’s cooperation with […]
Chinese Biotech Firm BioCytogen Raises RMB970 Million comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
Seattle Biotech Startup Led By Adaptive, Fred Hutch Vets Raises $16M For Rapid Drug Development Tech
2020-09-01T07:41:07.470014-04:00https://www.thetrustedinsight.com/investment-news/seattle-biotech-startup-led-by-adaptive-fred-hutch-vets-raises-16m-for-rapid-drug-development-tech-20200901945/
Lumen Bioscience today announced a $16 million Series B round to help support its novel approach to rapid and low-cost drug development. The company has come up with a way to produce orally-delivered antibodies and other biologics by using a bioengineered bright green algae called Spirulina. It has three clinical programs to treat gastrointestinal diseases including C. difficile, norovirus, and traveler’s diarrhea. Lumen CEO Brian Finrow said the company’s technology lowers the cost of biologic drugs by a factor of 1,000 or more.
Chinook Therapeutics Raises $106M As It Prepares To Merge With Aduro Biotech
2020-08-19T14:01:08.672331-04:00https://www.thetrustedinsight.com/investment-news/chinook-therapeutics-raises-106m-as-it-prepares-to-merge-with-aduro-biotech-20200819303/
Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, raised an additional $106 million just before its planned merger with Aduro Biotech. Chinook said it will have at least $275 million in operating capital following the investment and merger. New investors include EcoR1 Capital, OrbiMed, funds managed by Rock Springs Capital, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech.
Top Vcs Eye Booming Biotech Ipo Market For Capital
2020-08-15T10:01:05.975832-04:00https://www.thetrustedinsight.com/investment-news/top-vcs-eye-booming-biotech-ipo-market-for-capital-20200815104/
The drug industry is shattering capital-raising records in 2020, as investors funnel money into pharmaceutical and biotech companies. Business Insider spoke with top venture capitalists about why this is happening and how they plan to take advantage. Several VCs said they are advising biotechs that are now considering going public earlier than expected because of the booming public market. Biotech is still a risky gambit, VCs say, but money has flowed into the space as other industries, clobbered by the pandemic, appear shakier than usual. For more stories like this, sign up here for our healthcare newsletter, Dispensed.
New Cyrus Biotechnology Antibody Structure Prediction Software “nextgen” Outperforms Schrödinger And Other Software In Third-party Test | Business Wire
2020-08-10T07:31:08.332358-04:00https://www.thetrustedinsight.com/investment-news/new-cyrus-biotechnology-antibody-structure-prediction-software-nextgen-outperforms-schrodinger-and-other-software-in-third-party-test-business-wire-20200810818/
SEATTLE--(BUSINESS WIRE)--New Cyrus software can help develop more effective and safe antibody biologic therapeutics. :
SEATTLE--(BUSINESS WIRE)--Cyrus Biotechnology, Inc., today announced it has developed new antibody structure prediction software, Cyrus NextGen, that is significantly more accurate than other leading methods according to a third-party test administered by BIOCAD. NextGen will allow the development of more effective and safe antibody biologic therapeutics by Cyrus and its partners across a range of disease indications.
Riverhead Capital Co-leads $186M Series B Round In Chinese Lepu Biotech – China Money Network
2020-08-06T07:41:07.778983-04:00https://www.thetrustedinsight.com/investment-news/riverhead-capital-co-leads-186m-series-b-round-in-chinese-lepu-biotech-china-money-network-eA3hJXx7PLZzaRHt8JmUi4-20200806669/
Chinese innovative biotech firm Lepu Biotech completed a nearly RMB1.291 billion(US$186 million) series B round of financing co-led by Riverhead Capital, Sunshine Insurance Group and Ping An Capital. SDIC Unity Capital, Haitong Innovation Capital Management and State New Central Enterprises Operating Investment Fund also participated in this round. Founded in 2018, Lepu Biotech is a […]
Riverhead Capital Co-Leads $186M Series B Round In Chinese Lepu Biotech comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
Riverhead Capital Co-leads $186M Series B Round In Chinese Lepu Biotech – China Money Network
2020-08-06T07:11:07.929169-04:00https://www.thetrustedinsight.com/investment-news/riverhead-capital-co-leads-186m-series-b-round-in-chinese-lepu-biotech-china-money-network-20200806661/
Chinese innovative biotech firm Lepu Biotech completed a nearly RMB1.291 billion(US$186 million) series B round of financing co-led by Riverhead Capital, Sunshine Insurance Group and Ping An Capital. SDIC Unity Capital, Haitong Innovation Capital Management and State New Central Enterprises Operating Investment Fund also participated in this round. Founded in 2018, Lepu Biotech is a Chinese biotech firm focusing on development of cancer diagnosis and therapy. The company, through its nine subsidiaries, has established a comprehensive industrial platform for target discovery, drug development, and drug production.
Singapore Biotech Startup Gero Raises $2.2M In Series A Round
2020-08-04T15:11:05.805363-04:00https://www.thetrustedinsight.com/investment-news/singapore-biotech-startup-gero-raises-22m-in-series-a-round-20200804559/
Gero plans to use the funds to continue developing its AI platform for analysing clinical and genetic data. The post Singapore biotech startup Gero raises $2.2m in Series A round appeared first on DealStreetAsia.
Biotech Stocks Catch Fire In 2020 As Coronavirus Pandemic Heats Up
2020-07-30T19:31:05.898823-04:00https://www.thetrustedinsight.com/investment-news/biotech-stocks-catch-fire-in-2020-as-coronavirus-pandemic-heats-up-investors-business-daily-20200730395/
Covid-19 could drive biotech stocks for years to come, experts say, as investors try to pinpoint the next big winner to churn out a vaccine or treatment. The post Why The Coronavirus Pandemic Could Influence Biotech Stocks For Years To Come appeared first on Investor's Business Daily.
Biotech Vico Therapeutics Raises $31M (€27 Million) In Series A Financing Round To Advance Therapies For Rare Central Nervous System Diseases
2020-07-29T22:41:06.524802-04:00https://www.thetrustedinsight.com/investment-news/biotech-vico-therapeutics-raises-31m-27-million-in-series-a-financing-round-to-advance-therapies-for-rare-central-nervous-system-diseases-95edPgqx8BE24NfTdax8uF-20200729349/
Biotech Vico Therapeutics Raises $31M (€27 Million) In Series A Financing Round To Advance Therapies For Rare Central Nervous System Diseases
2020-07-29T07:01:06.595651-04:00https://www.thetrustedinsight.com/investment-news/biotech-vico-therapeutics-raises-31m-27-million-in-series-a-financing-round-to-advance-therapies-for-rare-central-nervous-system-diseases-20200729267/
LEIDEN, Netherlands, July 29, 2020 /PRNewswire/ -- Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that it has raised $31 million (€27 million) in a Series A...
Chinese Biotech Startup Harbour Biomed Secures $102.8M In Series C Round – China Money Network
2020-07-10T07:11:07.177460-04:00https://www.thetrustedinsight.com/investment-news/chinese-biotech-startup-harbour-biomed-secures-1028m-in-series-c-round-china-money-network-20200710235/
Harbour BioMed, a Shanghai-based biotechnology company focusing on cancer screening, today announced completion of its US$102.8 Million series C round financing to accelerate development of its growing portfolio of next generation biologics targeting cancer, immunologic diseases, and COVID-19. The financing was led by Hudson Bay Capital; followed by OrbiMed, Country Garden VC, GTJA Investment Group, […]
Chinese Biotech Startup Harbour BioMed Secures $102.8M In Series C Round comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
Ai-driven Biotech Company Neox Raises $10M Pre-a Round – China Money Network
2020-07-06T07:01:08.726309-04:00https://www.thetrustedinsight.com/investment-news/ai-driven-biotech-company-neox-raises-10m-pre-a-round-china-money-network-20200706900/
Beijing-based neoX Biotech today announced the completion of a US$10 million pre-A round financing co-led by Vision Plus Capital and Sequoia Capital China. Existing investor Morningside Venture Capital also participated. Proceeds oth the round will be mainly used for talent team construction, expansion of high-throughput laboratory, and cooperation in drug development pipelines. neoX Biotech previously […]
AI-Driven Biotech Company neoX Raises $10M Pre-A Round comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
Zero2ipo Leads $14M Series B Round In Chinese Biotech Firm Sophonix – China Money Network
2020-06-23T07:06:10.093151-04:00https://www.thetrustedinsight.com/investment-news/zero2ipo-leads-14m-series-b-round-in-chinese-biotech-firm-sophonix-china-money-network-20200623111/
Chinese biotechnology company Sophonix has recently completed a RMB100 million (US$14.14 million) series B funding round led by Zero2IPO Asset Management. Delian Capital, Anlong Fund, GoldTech Capital and existing investor ETP Fund also participated. Established in July 2017, Sophonix focuses on the development, production and sales of in vitro diagnostic instruments and reagents, providing accurate […]
Zero2IPO Leads $14M Series B Round In Chinese Biotech Firm Sophonix comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
Biotech Progenity Prices Ipo At $15 A Share, Midpoint Of Its Range
2020-06-19T11:31:09.587808-04:00https://www.thetrustedinsight.com/investment-news/biotech-progenity-prices-ipo-at-15-a-share-midpoint-of-its-range-20200619950/
Biotech Progenity Inc. priced its initial public offering on Friday at $15 share, the midpoint of its price range. The company sold 6.8 million shares to raise $100.5 million. The share will start trading later Friday on Nasdaq under the ticker symbol "PROG." Piper Sandler, Wells Fargo, Baird, Raymond James and BTIG were underwriters on the deal. Proceeds will be used for R&D and for working capital and general corporate purposes.
Chinese Biotech Firm Jw Therapeutics Closes $100M Series B Round – China Money Network
2020-06-10T08:31:05.888971-04:00https://www.thetrustedinsight.com/investment-news/chinese-biotech-firm-jw-therapeutics-closes-100m-series-b-round-china-money-network-EKVr7WUKPk2ndfLEtHj7zD-20200610246/
JW Therapeutics, a Shanghai-based clinical-stage biopharmaceutical company, has completed of a US$100 million series B round financing co-led by CPE and Mirae Asset. CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, and WuXi AppTec also participated in the […]
Chinese Biotech Firm JW Therapeutics Closes $100M Series B Round comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.
Chinese Biotech Firm Jw Therapeutics Closes $100M Series B Round – China Money Network
2020-06-10T07:01:09.259173-04:00https://www.thetrustedinsight.com/investment-news/chinese-biotech-firm-jw-therapeutics-closes-100m-series-b-round-china-money-network-20200610219/
JW Therapeutics, a Shanghai-based clinical-stage biopharmaceutical company, has completed of a US$100 million series B round financing co-led by CPE and Mirae Asset. CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, and WuXi AppTec also participated in the round. This round of financing brings the total capital raised to over US$200 million.
Xconomy: Atlas Venture Raises $400M Fund To Seed Another New Set Of Biotechs
2020-06-05T09:31:06.495541-04:00https://www.thetrustedinsight.com/investment-news/xconomy-atlas-venture-raises-400m-fund-to-seed-another-new-set-of-biotechs-20200605987/
Another venture capital firm that backs biotechs has raised a multimillion-dollar fund—money the firm, Cambridge, MA-based Atlas Venture, says it will use to continue creating and funding companies that are creating new medicines. Atlas revealed Friday that it closed its 12th fund after raising $400 million, a total that pushes the amount the company has […]
Seattle Biotech Startup Athira Raises $85M To Develop Therapies For Alzheimer’s And Parkinson’s
2020-06-04T10:31:09.329814-04:00https://www.thetrustedinsight.com/investment-news/seattle-biotech-startup-athira-raises-85m-to-develop-therapies-for-alzheimers-and-parkinsons-20200604901/
The foundation of Athira Pharma began while Leen Kawas was earning her Ph.D. in molecular pharmacology at Washington State University nearly a decade ago. Fast forward to today and the Seattle biotech startup is inching closer to FDA approval for its drug therapy that can restore brain function and help people suffering from brain diseases such as Alzheimer’s and Parkinson’s. Investors are betting big on the company, which announced a giant $85 million Series B investment round Thursday to help fuel late-stage development of its lead therapeutic candidate called NDX-1017.
Benchling Raises $50M Series D To Accelerate Biotech Revolution
2020-05-28T21:01:08.856659-04:00https://www.thetrustedinsight.com/investment-news/benchling-raises-50m-series-d-to-accelerate-biotech-revolution-20200528489/
Life sciences R&D platform to expand product suite and fuel biotech breakthroughs tackling COVID-19 to cancer to climate change SAN FRANCISCO, May 28, 2020-- Benchling, the leading life sciences R&D cloud platform, announced it closed $50 million in Series D funding led by Alkeon and joined by new investors Spark Capital, Lux Capital and ICONIQ Partners, as well as existing investors Thrive Capital, Benchmark and Menlo Ventures.
Biotech R&d Software Startup Benchling, Started By Mit Undergrads, Scores $850M Valuation Amid Coronavirus Pandemic
2020-05-28T07:31:08.843219-04:00https://www.thetrustedinsight.com/investment-news/biotech-rd-software-startup-benchling-started-by-mit-undergrads-scores-850m-valuation-amid-coronavirus-pandemic-20200528420/
Forbes Under 30 alum Sajith Wickramasekara scores an $850 million valuation for his biotech R&D startup Benchling. Amid the coronavirus pandemic, the company is helping big biotech companies work on potential therapeutics and vaccines for Covid-19.
Venture Capital Found Its Footing In Biotech. Then Came The Virus.
2020-05-27T10:55:06.882755-04:00https://www.thetrustedinsight.com/investment-news/venture-capital-found-its-footing-in-biotech-then-came-the-virus-20200527348/
There's been no better time for venture firms to invest in drug startups than the past several years. But when a virus upended the world, it raised new questions about what types of investors and investments would succeed moving forward.
Nautilus Biotechnology Raises $76M In Series B Funding To Be The First To Quantify The Human Proteome
2020-05-21T23:31:05.995345-04:00https://www.thetrustedinsight.com/investment-news/nautilus-biotechnology-raises-76m-in-series-b-funding-to-be-the-first-to-quantify-the-human-proteome-20200521070/
Nautilus Biotechnology Raises $76 Million in Series B Funding to Be the First to Quantify the Human Proteome Vulcan Capital-led investment will enable Nautilus to bring a next-generation, single-molecule proteomics platform to market SAN CARLOS, Calif & SEATTLE, May 21, 2020-- Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, today announced it has raised $76 million in an oversubscribed Series B offering that closed on Monday, May 18, 2020. Nautilus’ total funding now exceeds $100 million.
Jeff Bezos Joins $76M Round For Secretive Biotech Startup Led By Isilon Co-founder, Stanford Scientist
2020-05-21T11:01:06.485423-04:00https://www.thetrustedinsight.com/investment-news/jeff-bezos-joins-76m-round-for-secretive-biotech-startup-led-by-isilon-co-founder-stanford-scientist-20200521019/
Parag Mallick spent more than 20 years studying the intersection of software engineering and life sciences to better understand predictive and personalized medicine. Then, one weekend, a light bulb went off. The Stanford professor and cancer researcher had a big idea. He needed to start a company. Mallick called his longtime friend Sujal Patel, the veteran Seattle tech entrepreneur who co-founded and sold Isilon Systems to EMC for $2.5 billion in 2010. “It didn’t take me very long to realize Parag was on to something,” Patel said in an interview with GeekWire this week.
Chinese Biotech Firm Vazyme Snags $78M In Series C Round
2020-05-08T07:06:12.494046-04:00https://www.thetrustedinsight.com/investment-news/chinese-biotech-firm-vazyme-snags-78m-in-series-c-round-20200508062/
The financing was led by state-owned China Life Insurance Group’s healthcare fund. The post Chinese biotech firm Vazyme snags $78m in Series C round appeared first on DealStreetAsia.
Venrock Raises Nearly $450M For Oversubscribed Biotech Fund
2020-04-25T14:31:06.670951-04:00https://www.thetrustedinsight.com/investment-news/venrock-raises-nearly-450m-for-oversubscribed-biotech-fund-20200425162/
New York venture firm Venrock has raised nearly $450 million for an evergreen vehicle that will invest in both private and public biotech companies. Not yet registered? Join today to access Venture Capital Journal's industry insights and updates.
Legend Biotech Raises $150.5m In Equity Financing At $1.95B Valuation
2020-04-03T07:16:06.973091-04:00https://www.thetrustedinsight.com/investment-news/legend-biotech-raises-1505m-in-equity-financing-at-195b-valuation-20200403718/
Legend's initial round of equity investment comes ahead of its planned move towards an IPO on a US bourse. The post Legend Biotech raises $150.5m in equity financing at $1.95b valuation appeared first on DealStreetAsia.
Xconomy: San Diego Biotech Entrepreneurs, Innovation Lead To “maturing” Ecosystem
2020-03-30T07:31:08.084064-04:00https://www.thetrustedinsight.com/investment-news/xconomy-san-diego-biotech-entrepreneurs-innovation-lead-to-maturing-ecosystem-20200330392/
The local biotech ecosystem is growing up thanks to its innovative science and collaborative ecosystem, advantages that put it nearly on par with the nation’s top life science regions, according to industry veterans. San Diego has long been considered a second-tier primary biopharma hub in terms of number of companies and venture capital raised, falling […]
Temasek Leads $70M Series C Round In Chinese Biotech Firm Abbisko – China Money Network
2020-03-26T07:06:12.105239-04:00https://www.thetrustedinsight.com/investment-news/temasek-leads-70m-series-c-round-in-chinese-biotech-firm-abbisko-china-money-network-20200326171/
Abbisko Therapeutics, a Chinese oncology focused biopharmaceutical company, recently announced the completion of a US$70 million Series C financing, led by Temasek, joined by existing investors including Qiming Venture Partners, Jianxin Capital, GIC, Lilly Asia Ventures, CICC Capital, Loyal Valley Capital. This financing brings the total equity capital that the company has raised since its […]
Temasek Leads $70M Series C Round In Chinese Biotech Firm Abbisko comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.